Roctavian, Hem A Gene Therapy, Sustains Drop in Bleeding Rates, Fase 3 Data Show

Roctavian, Hem A Gene Therapy, Sustains Drop in Bleeding Rates, Fase 3 Data Show

Notícias sobre hemofilia hoje

Imagem

Please enable the javascript to submit this form

Apoiado por bolsas educacionais da Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics e uniQure, Inc.

SSL essencial